Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options.

ABSTRACT: With mortality rates of liver cancer doubling in the last 20 years, this disease is on the rise and has become the fifth most common cancer in men and the seventh most common cancer in women. Hepatocellular carcinoma (HCC) represents approximately 90% of all primary liver cancers and is a major global health concern. Patients with HCC can be managed curatively with surgical resection or with liver transplantation, if they are diagnosed at an early stage. Unfortunately, most patients with HCC present with advanced stages of the disease and have underlying liver dysfunction, which allows only 15% of patients to be eligible for curative treatment. Several different treatment modalities are available, including locoregional therapy radiofrequency ablation, microwave ablation, percutaneous etha

SUBMITTER: Ghavimi S 

PROVIDER: S-EPMC7438354 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature